Federal contract award
HT009025FG1210047
RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENTS WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | GPC COMPONENT PROGRAM MANAGER |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | HT001424A0002 |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $25.3K |
| Current contract value | $25.3K |
| Potential contract value / ceiling | $25.3K |
| Start date | Dec 19, 2024 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Dec 19, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 19, 2024 | 0 | $25.3K | RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENTS WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.